Study Region Study design Sex Sex Age (yrs) Study duration (mo) RTX administration Proteinuria prior to RTX
Male Female
Cravedi 2007 Italy Matched-cohort study 8 4 57.0±13.0 12 B cell-driven treatment* 10.3±8.9
Sugiura 2010 Japan Prospective clinical trial 2 2 66.5±8.7 6 1×375 mg/m2 (n = 4) (maximum 500 mg) 4.3±2.6
Ramachandran 2016 India Prospective clinical trial —— —— —— 6 100 mg of RTX (n = 6) 12.1±10.8
Moroni 2017
Italy
Prospective single-center experience
23
11
52.8±15.2
24
1×375 mg/m2 (n = 18) 2×375 mg/m2 (n = 16)
11.9±8.2
Bagchi 2018 India Multicentric retrospective study 14 7 33.3±12.3 12 two doses of RTX (500mg each) infusion 7 days apart 6.2±2.2
Fenoglio (LD) 2020 Italy Prospective cohort experience 5 9 64.4±10.8 24 1×375 mg/m2 (n = 14) 7.5±4.8
Remuzzi 2002 Italy Prospective single-center experience —— —— 50.1±45.6 20 4×375 mg/m2 8.6±1.5
Ruggenenti 2003 Italy Prospective single-center experience —— —— 52.5±19.6 12 4×375 mg/m2 8.6±4.2
Ruggenenti (pro) 2006 Italy Retrospective cohort and prospective cohort 4 5 51.2±13.2 12 4×375 mg/m2 8.9±5.3
Fervenza 2008 Canada Prospective single-center experience 13 2 47.0±8.0 12 4×375 mg/m2 13.0±5.7
Fervenza 2010 Canada Prospective single-center experience 17 3 48.6±12.9 24 4×375 mg/m2 11.9±4.9
Busch 2013 Germany Prospective single-center experience 10 4 47.0±14.0 12 4×375 mg/m2 8.6±1.5